All In Biotech

Free tool

FAERS Monitor: Cleocin T

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 050615 or its brand name (Cleocin T, Clindamycin Phosphate). Reports on generic versions are filed under their own applications.

Reports

3,969

Serious

2,541

64% of reports

Hospitalization

1,194

Death reported

292

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective386
  • rash285
  • off label use258
  • drug hypersensitivity240
  • nausea227
  • diarrhoea226
  • fatigue211
  • pruritus186
  • pain178
  • condition aggravated151
  • headache136
  • dyspnoea135
  • pyrexia122
  • vomiting117
  • malaise111

Reports by year received

View as table
YearReports
200422
200563
200662
200715
200830
200948
201093
201183
2012115
2013109
2014117
2015147
2016277
2017200
2018253
2019298
2020227
2021217
2022312
2023325
2024317
2025345
2026293

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,190 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
drug hypersensitivitySignal2406.65.81,139
rashSignal2853.53.1508
condition aggravatedSignal1512.62.3153
pruritusSignal1862.62.2179
pyrexia1221.91.649
diarrhoea2261.91.691
off label use2581.61.454
drug ineffective3861.61.480
pain1781.51.334
nausea2271.51.341
fatigue2111.41.329
malaise1111.31.19
vomiting1171.31.19
dyspnoea1351.31.17
headache1361.11.03

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.